RU2002130247A - OXADIAZOLE DERIVATIVES WITH ANTITUMER ACTION - Google Patents

OXADIAZOLE DERIVATIVES WITH ANTITUMER ACTION

Info

Publication number
RU2002130247A
RU2002130247A RU2002130247/04A RU2002130247A RU2002130247A RU 2002130247 A RU2002130247 A RU 2002130247A RU 2002130247/04 A RU2002130247/04 A RU 2002130247/04A RU 2002130247 A RU2002130247 A RU 2002130247A RU 2002130247 A RU2002130247 A RU 2002130247A
Authority
RU
Russia
Prior art keywords
optionally substituted
ness
compound
pharmaceutical composition
prodrug
Prior art date
Application number
RU2002130247/04A
Other languages
Russian (ru)
Other versions
RU2275371C2 (en
Inventor
Такаюки ЁШИОКА
Рюйи МАЕКАВА
Фумихико ВАТАНАБЕ
Original Assignee
Шионоги & Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шионоги & Ко., Лтд. filed Critical Шионоги & Ко., Лтд.
Publication of RU2002130247A publication Critical patent/RU2002130247A/en
Application granted granted Critical
Publication of RU2275371C2 publication Critical patent/RU2275371C2/en

Links

Claims (8)

1. Фармацевтическая композиция для терапии или профилактики онкологических заболеваний, содержащая в качестве активного ингредиента соединение общей формулы (I), его пролекарство, фармацевтически приемлемую соль или сольват1. A pharmaceutical composition for the treatment or prevention of cancer, comprising, as an active ingredient, a compound of general formula (I), a prodrug thereof, a pharmaceutically acceptable salt or solvate thereof
Figure 00000001
Figure 00000001
 где R1 означает NHOH, гидрокси или (низш.)алкилокси,where R 1 means NHOH, hydroxy or (ness.) alkyloxy, R2 означает водород, необязательно замещенный (низш.)алкил, необязательно замещенный арил, необязательно замещенный аралкил, необязательно замещенный гетероарил или необязательно замещенный гетероарилалкил,R 2 means hydrogen, optionally substituted (ness.) Alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl, R3 означает водород, необязательно замещенный (низш.)алкил, необязательно замещенный арил, необязательно замещенный аралкил, необязательно замещенный гетероарил или необязательно замещенный гетероарилалкил,R 3 means hydrogen, optionally substituted (ness.) Alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl, R4 означает необязательно замещенный арилен или необязательно замещенный гетероарилен,R 4 means optionally substituted arylene or optionally substituted heteroarylene, R5 означает необязательно замещенный арил, необязательно замещенный гетероарил или необязательно замещенную неароматическую гетероциклическую группу.R 5 means an optionally substituted aryl, an optionally substituted heteroaryl, or an optionally substituted non-aromatic heterocyclic group. 2. Соединение формулы (I')2. The compound of formula (I ')
Figure 00000002
Figure 00000002
 где R6 означает NHOH, гидрокси или (низш.)алкилокси,where R 6 means NHOH, hydroxy or (ness.) alkyloxy, R7 означает водород, метил, изопропил, изобутил, бензил или индол-3-илметил,R 7 means hydrogen, methyl, isopropyl, isobutyl, benzyl or indol-3-ylmethyl, R8 означает водород или необязательно замещенный (низш.)алкил,R 8 means hydrogen or optionally substituted (ness.) Alkyl, R9 означает фенилен или 2,5-тиофендиил,R 9 means phenylene or 2,5-thiophenediyl, R10 означает необязательно замещенный тиенил, необязательно замещенный фурил или необязательно замещенный пиридил, его пролекарство или фармацевтически приемлемая соль или сольват.R 10 means optionally substituted thienyl, optionally substituted furyl or optionally substituted pyridyl, a prodrug thereof or a pharmaceutically acceptable salt or solvate thereof. 3. Соединение формулы3. The compound of the formula
Figure 00000003
Figure 00000003
Figure 00000004
Figure 00000004
Figure 00000005
Figure 00000005
Figure 00000006
Figure 00000006
Figure 00000007
Figure 00000007
Figure 00000008
Figure 00000008
 его пролекарство или фармацевтически приемлемая соль или сольват.a prodrug thereof or a pharmaceutically acceptable salt or solvate thereof. 4. Фармацевтическая композиция, содержащая в качестве активного ингредиента соединение по п.2 или 3.4. A pharmaceutical composition comprising, as an active ingredient, a compound according to claim 2 or 3. 5. Фармацевтическая композиция по п.4 в качестве агента для терапии или профилактики онкологического заболевания.5. The pharmaceutical composition according to claim 4 as an agent for the treatment or prevention of cancer. 6. Фармацевтическая композиция по п.4 в качестве агента для профилактики метастазирования.6. The pharmaceutical composition according to claim 4 as an agent for the prevention of metastasis. 7. Применение соединения по п.2 или 3 для получения лекарственного средства для терапии опухолевого заболевания.7. The use of a compound according to claim 2 or 3 for the manufacture of a medicament for the treatment of a tumor disease. 8. Способ лечения опухолевого заболевания у млекопитающего введением млекопитающему, включая человека, терапевтически эффективного количества соединения по п.2 или 3.8. A method of treating a tumor of a disease in a mammal by administering to the mammal, including humans, a therapeutically effective amount of a compound according to claim 2 or 3.
RU2002130247/04A 2000-04-21 2001-04-16 Oxadiazole derivatives possessing anti-tumor effect, medicinal agent comprising thereof and method for treatment RU2275371C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000120234 2000-04-21
JP2000-120234 2000-04-21

Publications (2)

Publication Number Publication Date
RU2002130247A true RU2002130247A (en) 2004-04-10
RU2275371C2 RU2275371C2 (en) 2006-04-27

Family

ID=18631080

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002130247/04A RU2275371C2 (en) 2000-04-21 2001-04-16 Oxadiazole derivatives possessing anti-tumor effect, medicinal agent comprising thereof and method for treatment

Country Status (16)

Country Link
US (2) US6720343B2 (en)
EP (1) EP1277744A4 (en)
JP (1) JP3974781B2 (en)
KR (1) KR100542780B1 (en)
CN (1) CN1199956C (en)
AU (2) AU4691601A (en)
BR (1) BR0110211A (en)
CA (1) CA2406685C (en)
HU (1) HUP0300619A3 (en)
MX (1) MXPA02010325A (en)
NO (1) NO324868B1 (en)
PL (1) PL203161B1 (en)
RU (1) RU2275371C2 (en)
TW (1) TWI294877B (en)
WO (1) WO2001083463A1 (en)
ZA (1) ZA200208307B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
WO2005012268A1 (en) * 2003-07-30 2005-02-10 Shionogi & Co., Ltd. Sulfonamide derivative having isoxazole ring
AU2005299851B2 (en) * 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
MEP43308A (en) * 2006-05-09 2011-02-10 Pfizer Prod Inc Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
KR100783585B1 (en) 2006-08-22 2007-12-07 한국생명공학연구원 Agent for prevention or treatment of cancer comprising oxadiazole urea compound obstructing activity of stat
CN104072489B (en) 2007-08-27 2017-07-07 达特神经科学(开曼)有限公司 Therapeutic isoxazole compounds
TW200930363A (en) * 2007-12-10 2009-07-16 Actelion Pharmaceuticals Ltd Novel thiophene derivatives
AR077969A1 (en) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv DERIVATIVES OF (TIO) MORFOLINA COMOMODULADORES DE S1P
TWI522361B (en) 2010-07-09 2016-02-21 艾伯維公司 Fused heterocyclic derivatives as s1p modulators
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TWI543984B (en) 2010-07-09 2016-08-01 艾伯維公司 Spiro-piperidine derivatives as s1p modulators
CN103450167A (en) * 2012-05-28 2013-12-18 南京大学 Acylhydrazone derivatives containing 1, 3, 4-oxadiazole and pyrazine ring and preparation method and uses thereof
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
KR20220123634A (en) 2019-10-31 2022-09-08 이스케이프 바이오, 인크. Solid form of S1P-receptor modulators
CN113264899B (en) * 2021-04-09 2022-06-14 台州学院 1,3,5-oxadiazine compound and preparation and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2207849C2 (en) * 1997-07-22 2003-07-10 Шионоги & Ко., Лтд. Composition for glomerulopathy treatment and prophylaxis, novel compounds comprising to thereof, pharmaceutical composition for inhibition of matrix metalloproteinases activity and composition for inhibition of collagenases of type iv
AU5647099A (en) 1998-09-11 2000-04-03 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure

Similar Documents

Publication Publication Date Title
RU2002130247A (en) OXADIAZOLE DERIVATIVES WITH ANTITUMER ACTION
RU2219167C2 (en) N-substituted aminotetralines as ligands for receptor of y5 of neuropeptide y useful in treatment of obesity and other disorders
RU2485131C2 (en) Pyridine derivatives substituted by heterocyclic ring and phosphonomethyl group, and antimycotic agent containing them
JP2004533444A5 (en)
EP1772142A3 (en) Organic compounds
RU2002124873A (en) Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing these derivatives, and intermediates for preparing said derivatives
JP2001526218A5 (en)
JP2003509349A5 (en)
JP2002525329A5 (en)
RU2012110380A (en) NEW 5-Fluorouracil Derivative
RU2002100058A (en) 1-Methylcarbapenem Crystal Derivatives
JP2008500378A5 (en)
RU2003118411A (en) 1-Methylcarbapenem Crystal Derivatives
RU2002123641A (en) S-4 carbonate-containing taxanes
RU2006103858A (en) METHOD FOR TREATING PROLIFERATIVE DISEASES
JP2002503714A5 (en)
RU2002101622A (en) Naphthoquinone derivatives and their use for the treatment and control of tuberculosis
JP2003520208A5 (en)
JP2003508543A5 (en)
RU98119076A (en) DERIVATIVES OF 2- (3H) -OXASOLONE AND THEIR APPLICATION AS SOX-2 INHIBITORS
JP2003516994A5 (en)
JP2003535890A5 (en)
CA2685043A1 (en) Use of iron chelator for the treatment of myocardial infarction
RU2007111754A (en) APPLICATION OF MIDOSTAURIN FOR TREATMENT OF GASTROINTESTINAL STOMAL TUMORS
JP2006514063A5 (en)